🔗 Permalink

Assignee profile:

Ascendis Pharma Bone Diseases A/S

City:

Hellerup

Country:

Denmark

Published Applications:

Last publication date:

2024-07-25

Patent Grants:

Last grant date:

2025-05-13

Top Inventors for applications by Ascendis Pharma Bone Diseases A/S

These are the the leading inventors for applications assigned to Ascendis Pharma Bone Diseases A/S:

Kennett Sprogøe 13 Holte, Denmark
Joachim Zettler 11 Heidelberg, Germany
Guillaume Maitro 11 Mannheim, Germany
Thomas Wegge 11 Heidelberg, Germany

Felix CLEEMANN 10 Mainz, Germany
Mathias Krusch 10 Hirschhorn, Germany
Lars Holten-Andersen 6 Vanløse, Denmark
David Brian Karpf 6 Mountain View, CA United States

Mathias Krusch 1 Hirschhom, Germany
Anja R. H. Skands 1 Hellerup, Denmark
Kennett SPROGØE 1 Hellerup, Denmark
Claus Strange 1 Heller, Denmark

Anja R.H. SKANDS 1 Hellerup, Denmark
Julia Baron 1 Heidelberg, Germany
Michael Duelund SØRENSEN 1 Hellerup, Denmark
Eric HOFFMANN 1 Heidelberg, Germany

David Brian Karpf 1 Palto Alto, CA United States
Felix Cleemann 1 Heidelberg, Germany
Michael Duelund Sørensen 1 Hellerup, Denmark
Kennett Sprogøe 1 Helleru, Denmark

Kennett Sprogøe 1 Hellerup, Denmark
Ken nett Sprogøe 1 Holte, Denmark

Recent patent applications by Ascendis Pharma Bone Diseases A/S

Ascendis Pharma Bone Diseases A/S based in Hellerup, DK has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-07-25 ✅ Patent 12,295,989 granted on 2025-05-13

US20240245755A1

Human necessities

Controlled-release PTH compound

#2 | 2024-04-18 ✅ Patent 12,214,020 granted on 2025-02-04

US20240123038A1

Human necessities

PTH prodrugs

#3 | 2023-11-30 ✅ Patent 11,918,628 granted on 2024-03-05

US20230381284A1

Human necessities

Controlled-release PTH compound

#4 | 2023-08-10 ✅ Patent 11,890,326 granted on 2024-02-06

US20230248836A1

Human necessities

Controlled-release PTH compound

#5 | 2023-07-13 ✅ Patent 11,857,603 granted on 2024-01-02

US20230218722A1

Human necessities

PTH compounds with low peak-to-trough ratios

#6 | 2023-04-20 ✅ Patent 11,793,861 granted on 2023-10-24

US20230121525A1

Human necessities

PTH prodrugs

#7 | 2022-03-24 ✅ Patent 12,403,182 granted on 2025-09-02

US20220088149A1

Human necessities

Liquid Pharmaceutical Formulations of PTH Conjugates

#8 | 2022-01-13

US20220008516A1

Human necessities

PTH Prodrugs

#9 | 2021-07-01

US20210196801A1

Human necessities

Starting Dose of PTH Conjugates

#10 | 2020-12-03

US20200376089A1

Human necessities

PTH PRODRUGS

#11 | 2020-11-19

US20200360488A1

Human necessities

PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS

#12 | 2020-11-19

US20200360487A1

Human necessities

PTH PRODRUGS

#13 | 2020-01-23 ✅ Patent 11,590,207 granted on 2023-02-28

US20200023041A1

Human necessities

Dosage regimen for a controlled-release PTH compound

#14 | 2019-09-19 ✅ Patent 11,759,504 granted on 2023-09-19

US20190282668A1

Human necessities

PTH compounds with low peak-to-trough ratios

#15 | 2019-07-25 ✅ Patent 12,453,778 granted on 2025-10-28

US20190224329A1

Human necessities

Incremental Dose Finding in Controlled-Release PTH Compounds

Also check out Ascendis Pharma Bone Diseases A/S's (Hellerup, Denmark) applicant profile with 14 patent applications submitted.

AssigneeID:

151226 ⎘